

PTO/SB/21 (01-03)

Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/722,049
	Filing Date	November 25, 2003
	First Named Inventor	Hennig
	Art Unit	
	Examiner Name	
Total Number of Pages in This Submission	Attorney Docket Number	21491

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation <input type="checkbox"/> Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<div>Remarks</div> <div>PTO Form 1449, References</div>		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual	Eileen M. Ebel
Signature	
Date	February 25, 2003

CERTIFICATE OF TRANSMISSION/MAILING			
I hereby certify that this correspondence is being transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313 on this date February 25, 2003			
Typed or printed	Eileen M. Ebel		
Signature		Date	February 25, 2003

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application

Inventor(s) M. Hennig, B. Loeffler, R. Thoma

Group:

Serial No. 10/722,049, filed November 25, 2003

Examiner:

For: CRYSTALS OF DPP-IV

INFORMATION DISCLOSURE STATEMENT

Nutley, New Jersey 07110
February 25, 2004

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:


Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, applicants respectfully direct the Examiner's attention to the documents listed on enclosed Form PTO-1449.

Documents C1 – C20 listed on Form PTO-1449 are enclosed.

Consideration of all the documents cited on Form PTO-1449 is requested.

Since the Information Disclosure Statement is submitted before the mailing of the first Office Action on the merits or within three months of the filing date for the above application, no fee is due.

Respectfully submitted,

A handwritten signature in cursive script, appearing to read "Eileen M. Ebel", written over a horizontal line.

Attorney for Applicant(s)

Eileen M. Ebel

(Reg. No. 37,316)

340 Kingsland Street

Nutley, New Jersey 07110

Telephone: (973) 235-4391

Telefax: (973) 235-2363

138849

[illegible]



Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				Complete if Known	
				Application Number	10/722,049
				Filing Date	November 25, 2003
				First Name Inventor	Hennig
				Group Art Unit	
				Examiner Name	
Sheet	2	Of	2	Attorney Docket Number	21491

NON PATENT LITERATURE DOCUMENTS

Examiner Initials [*]	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium catalog, etc.), date, page(s), volume- issue number(s), publisher, city and/or country where published	T ²
	C1	Buhling, F. et al. Nat. Immun. 13, 270-279 (1994)	
	C2	Cunningham, D.F. & O'Connor B., Biochim. Biophys. Acta 1343, 160-186 (1997)	
	C3	Franco, R., et al., Immunol. Rev. 161, 27-42 (1998)	
	C4	Gorrell, M.D., et al. Cell. Immunol. 134, 205-215 (1991)	
	C5	Hartel, S. et al., Histochemistry 89, 151-161 (1988)	
	C6	Hildebrandt, M., et al., Clin Sci 99, 93-104 (2000)	
	C7	Hinke, S.A., et al., J. Biol. Chem. 275, 3827-3834 (2000)	
	C8	Holst., J.J. & Deacon, C.F. Diabetes 47, 1663-1670 (1998)	
	C9	Hopsu-Havu, V.K. & Glenner, G.G., Histochemie 7, 197-201 (1966)	
	C10	Ikehara, Y., et al., Methods Enzymol. 244, 215-227 (1994)	
	C11	Iwaki-Egawa, S., J. Biochem. 124, 428-433 (1998)	
	C12	Lambeir, A.M., et al., FEBS Lett. 507, 327-330 (2001)	
	C13	Loster, K., Biochem. Biophys. Res. Commun. 217, 341-348 (1995)	
	C14	McCaughan, G.W., et al. Hepatology 11, 534-544 (1990)	
	C15	Ohtsuki, T. et al., J. Dermatol. Sci. 22, 152-160 (2000)	
	C16	Pospisilik, J.A. et al., Diabetes 51, 2677-2683 (2002)	
	C17	Tanaka, T., J. Immunol. 149, 481-486 (1992)	
	C18	Torimoto, Y., et al., J. Immunol. 147, 2514-2517 (1991)	
	C19	Villhauer, E.B., et al., J. Med. Chem. 45, 2362-2365 (2002)	
	C20	Von Bonin, et al. Immunol. Rev. 161, 43-53 (1998)	
Examiner Signature		DATE CONSIDERED	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation or abstract is attached.

138839